Resources | ILife Consulting

Testimonials

02:34

ImCheck Therapeutics | Paul Frohna, CMO

ImCheck Therapeutics is designing and developing novel immunotherapeutics that target members of the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules with an initial focus on gamma delta (γ9δ2) T cells. Interview with Paul Frohna, Chief Medical Officer

02:55

Smart Immune | Karine Rossignol, CEO

Smart Immune is a clinical-stage biotechnology company developing ProTcell™a thymus-empowered cell therapy platform to fully and rapidly re-arm the immune system, enabling next generation allogeneic T-cell therapies for all. Interview with Karine Rossignol, CEO and co-founder

02:57

Carthera | Carole Desseaux, CCO

Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders. Interview with Carole Desseaux, Chief Clinical Officer

Case studies

TRAINING & UPSKILLING TO IMPROVE CLINICAL TRIAL OUTCOME

An open-label, multicenter, non-randomized interventional roll over trial for relapsing glioblastoma patients

RESCUING AN EXTENSION PHASE

A randomized, double blind, multicentre, multinational, placebo controlled, single parallel escalating dose safety and efficacy study

Our clients' newsflow referencing ILife Consulting

ImCheck Therapeutics
March 26, 2020

First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta

T Cell-Activating Immunotherapy

See Press Release

ImCheck Therapeutics
EVICTION study at SITC 2020

Preliminary Results in Solid Tumor Patients with ICT01, a First-in-Class, γ9δ2 T Cell Activating Antibody Targeting Butyrophilin 3A

See Poster

Smart Immune
Oct 13, 2021

Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcellTM) for AML and ALL
Trial to commence in November 2021

See Press Release

ImCheck Therapeutics
EVICTION-2 study at SITC 2022

Enhancing the Anti-tumor Immunity and Therapeutic Potential of ICT01 a Butyrophilin 3A γ9δ2 T Cell-Activating Monoclonal Antibody with Low Dose IL-2 in Patients with Advanced Solid Tumors

See Poster